Neutralizing antibodies against SARS-CoV-2 virus after vaccination in patients with neurofibromatosis type 1

Signal Transduct Target Ther. 2023 Jun 2;8(1):233. doi: 10.1038/s41392-023-01498-1.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • COVID-19*
  • Humans
  • Neurofibromatosis 1*
  • SARS-CoV-2
  • Vaccination

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral